Affiliations
Kole R DeGolier, Etienne Danis, Marc D'Antonio, Jennifer Cimons, Michael Yarnell, Ross M Kedl, M Eric Kohler, James P Scott-Browne, Terry J Fry
DOI: 10.1038/s41590-024-02034-1
Abstract
Although chimeric antigen receptor (CAR) T cells are effective against B-lineage malignancies, post-CAR relapse is common, and efficacy in other tumors is limited. These challenges may be addressed through rational manipulations to control CAR T cell function. Here we examine the impact of cognate T cell antigen experience on subsequent CD8
Keywords
chimeric antigen receptor (CAR) T cells,CD15,CD8
Produits associés
| Numéro de catalogue | Nom du produit | Description | Cible |
|---|
+86-027-65523339
Bâtiment C, No. 666, Rue Shendunsi, Wuhan, 430206, Chine
中文
English
한국어
日本語
Español
Français
Русский